Shionogi & Co., Ltd.

2019/10/11: Shionogi Received “2019 Award for Excellence in Corporate Disclosure” for Three Consecutive Year from the Securities Analysts Association of Japan (SAAJ)
2019/10/11: Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
2019/10/04: M3 and Shionogi Joint Venture for Disease Solution - Establishment of Stream-I, Inc. -
2019/10/03: Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens APEKS-NP trial met primary endpoint of non-inferiority of cefiderocol compared to meropenem
2019/10/02: Congress Presentation on Clinical Study of S-600918, a Drug Candidate for the Treatment of Refractory/Unexplained Chronic Cough - Favorable Results of Phase II Study Presented at the European Respiratory Society International Congress (ERS 2019)
2019/09/30: 【Notice Regarding Acquisition of Own Shares and Cancellation of Treasury Shares (Acquisition of own shares pursuant to the provisions of Article 165, paragraph 2 of the Companies Act and cancellation of treasury stocks pursuant to the provisions of Article 178 of the Companies Act)】
2019/09/27: Shionogi to Present New Data at IDWeek 2019 - Including Cefiderocol Phase III APEKS-NP Trial as Late-breaker Oral Presentation
2019/09/06: Shionogi to Announce Personnel Reassignment
2019/09/02: Positive Results for XOFLUZATM Global Phase III Study (MINISTONE-2) in Children with Influenza
2019/09/02: Shionogi Announces Positive Post-Exposure Prophylaxis Results for XOFLUZA® in Phase III Study (BLOCKSTONE) of Influenza Virus Infection in Household Members
2019/09/02: Special Drug Use Survey for XOFLUZA® Announced at OPTIONS X - Analysis of Rate of Appearance and Clinical Course of Mutated Viruses at Position 38 in PA Protein for Influenza A/H1N1pdm and A/H3N2 Presented-
2019/09/02: The Results of Analyses of PA/I38X-substituted Viruses in XOFLUZA® Clinical Studies
2019/08/29: Shionogi Announces XOFLUZA® Tablets 20mg for The Treatment of Influenza Types A and B in Patients 12 years of Age and older Approved in Taiwan.